FDA decision on Eisai/Biogen Alzheimer’s drug lecanemab expected by January 07-Jul-2022 By Rachel Arthur Eisai and Biogen’s Alzheimer’s drug lecanemab has been accepted for the accelerated approval pathway with the FDA.